Skip to main content

Table 1 Summary of studies included in the meta-analysis

From: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials

Study No. of patients Inclusion period Group Histology (WHO grade, No.) Stage Radiotherapy Chemotherapy
     I II III    Concurrent Adjuvant
Kwong et al, [10] 2004 165 1995-2001 CCRT RT 1 1 14 4 95
50
AJCC stage II -IV, any T, any N 2.5GyFx/5days/wk, primary site- 68Gy, Nodes- 66Gy, + 10Gy boost dose were given for pharyngeal extension and residual nodes UFT 200 mg/day/7 days a wk Alternating Cisplatin 100 mg/m2 day1 and 5FU 1 gm/m2/d day 1-3 and VBM regimen (Vincristine 2 mg, bleomycin 30 mg, MTX 150 mg/m2) every 3wks for 6 cycles.
Chan et al, [11] 2005 350 1994-1997 CCRT RT 2 1 12 7 160 168 AJCC stage II to IV, any T, any N, M0 66Gy in 33Fx per 6.5 wks + additional boost in case of parapharyngeal extension, residual neck nodes, and/or residual nasopharyngeal disease (Brachytherapy) Cisplatin 40 mg/m2 in day1 weekly None
Wee et al, [12] 2005 221 1997-2003 CCRT RT - 100% grade II and III AJCC stage II to IV, any T, any N 70Gy (2Gy/d in 5Fx/wk for 7 wks) CDDP 25 mg/m2/d for 4 days, alternatively 30/30/40 mg/m2/d for 3 days if patient starts RT on Wednesday CDDP 20 mg/m2/d × 4 days, 5FU 1000 mg/m2/d × 4 days
Lee et al, [13, 18] 2005,2010 348 1999-2004 CCRT RT - 100% grade II AJCC stage III and IV, any T, N2 or N3, M0 ≥66Gy (2Gy/Fx/d, 5Fx/wk) + additional boosts to the parapharyngeal space, the primary or nodal sites when indicated not exceeding 20Gy Cisplatin 100 mg/m2 × 3wks on days 1,22,43 CDDP 80 mg/m2 and 5FU 1000 mg/m2/d every 4 wks on days 71,99 and 127
Zhang et al, [14] 2005 115 2001-2003 CCRT RT - 100% grade II and III AJCC stage III and IV, any T, N2 or N3, M0 70-74Gy (2Gy/Fx/d, 5fx/wk) + additional boost in case of parapharyngeal extension, residual neck nodes and/or residual nasopharyngeal disease 6× Oxaliplatin 70 mg/m2 weekly None
Lee et al, [15, 17] 2006,2009 93 1999-2004 CCRT RT - 100% grade II AJCC stage III and IV, T3-4, N0-1, M0 ≥66Gy (2Gy/Fx/d, 5Fx/wk) + Additional boosts to the parapharyngeal space, the primary or nodal sites when indicated not exceeding 20Gy Cisplatin 100 mg/m2 × 3wks on days 1,22,43 Cisplatin 80 mg/m2 and 5FU 1000 mg/m2/d on days 71,99 and 127
Chen et al, [16] 2008 316 2002-2005 CCRT RT - 100% grade II and III AJCC stage III and IVA-B, T1-4, N0-3, ≥68Gy (2Gy/Fx/d, 5Fx/wk) in 7 weeks + additional boost in case of parapharyngeal extension, residual neck nodes and/or residual nasopharyngeal disease Cisplatin 40 mg/m2 day1 weekly × 7wks Cisplatin 80 mg/m2 day1 and 5FU 800 mg/m2/d on days1-5 every 4wks for 3 cycles.
  1. Abbreviation: CDDP, Cisplatin; UICC, International Union Against Cancer; AJCC, American Joint Committee on cancer; FU, Fluorouracil